Partnering Delenex is a product-focused biotech company demonstrating the clinical utility of its PENTRA® antibody fragments in serious medical conditions with high unmet need. We are interested in finding partners for the following PENTRA® products in these areas:

Near-term (immediate licensing window)
  • Phase 2-ready project in Osteoarthritis (OA) Delenex has shown good safety and pharmacology of the DLX105 compound, when used for intra-articular knee injections in OA patients, in a recently concluded Phase 1b study. Since a full Phase 2 study in this indication exceeds our financial and operational capabilities, we are seeking a partner to advance an injectable form of the compound in this indication.

  • Pre-clinical project in Neuroscience Published data in rodents show that PENTRA® antibodies have potential to reach the brain, penetrate brain tissue, and have a pharmacodynamic effect. We are seeking partners to bring PENTRA® antibodies to animal proof of concept and to human trials, either for our anti-Aß compound (DLX212) in Alzheimer’s Disease, or our anti-TNFa compound (DLX105) in brain inflammation, for instance against complications of traumatic brain injury (TBI).

Medium-term (licensing window starting mid- to end 2012)
  • Dermatology We are actively engaged in proving the skin penetration of our pipeline antibodies, as well as clinical data showing pharmacodynamic activity upon local delivery in a dermatology indication. We will be seeking partners based on our clinical data mid-2012.

  • Gastro-Intestinal Diseases Based on the demonstrated relevance of systemic anti-TNFa therapy in inflammatory bowel disease (IBD), we are planning clinical proof of concept studies of a local antibody therapy in this indication, reading out end 2012.

  • Acute inflammation The long half-life of currently marketed antibodies make them less suitable to treat acute inflammatory events or short-duration ‘flares’ of underlying inflammatory conditions. PENTRA® antibodies, thanks to their short half-life and excellent tissue penetration, are ideally suited for acute indications. We are starting a clinical proof of concept trial in a well-selected patient population suffering from such flares, reading out end 2012.
      Further information
      Dr. Eric de La Fortelle
      CEO
      Contact...